Last reviewed · How we verify
Blepharoconjunctivitis
Approved treatments
- Ramycin
Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins. - Cortisporin · Pfizer
- Garamycin · Merck & Co.
- Tobi · Novartis
- Cortifoam · Pfizer
- Klaron · Merck & Co.
- Trimethoprim · Dr Reddys Labs Sa
- Cortone
- Decadron · Generic (originally Merck)
- Vantobra · Pfizer
- Gentamicin · Merck & Co.
- Nebcin · University Hospital, Lille
- Cortisporin · Pfizer
- Cortef · Generic (originally Merck/Upjohn)
- Cortisporin · Pfizer
- Gramoderm · Pfizer
- Cortisol · University of Zurich
- Prelone · Generic (originally Schering)
- prednisolon · Hannover Medical School
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Blepharoconjunctivitis patent landscape — cliff calendar, originator estates, attackable patents
- Blepharoconjunctivitis treatment landscape brief
- Blepharoconjunctivitis treatment updates RSS
Frequently asked questions about Blepharoconjunctivitis
What drugs treat Blepharoconjunctivitis?
Tracked treatments include Ramycin, Cortisporin, Garamycin, Tobi, Cortifoam, Klaron, Trimethoprim, Cortone.
What is the treatment for Blepharoconjunctivitis?
Standard treatment for Blepharoconjunctivitis includes Ramycin, Cortisporin, Garamycin, Tobi, Cortifoam. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Blepharoconjunctivitis patent cliff · Blepharoconjunctivitis CI report
- Treatment: Ramycin
- Treatment: Cortisporin · Pfizer
- Treatment: Garamycin · Merck & Co.
- Treatment: Tobi · Novartis
- Treatment: Cortifoam · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing